Diaceutics (LON:DXRX) Rating Reiterated by Canaccord Genuity Group

Canaccord Genuity Group reaffirmed their buy rating on shares of Diaceutics (LON:DXRX) in a research note issued to investors on Tuesday, MarketBeat reports. Canaccord Genuity Group currently has a GBX 160 ($2.11) price objective on the stock.

Diaceutics Trading Down 0.7 %

Diaceutics stock opened at GBX 133 ($1.76) on Tuesday. The company has a 50 day moving average price of GBX 128.68 and a 200 day moving average price of GBX 118.03. The company has a debt-to-equity ratio of 2.95, a quick ratio of 9.92 and a current ratio of 6.40. Diaceutics has a 52 week low of GBX 82 ($1.08) and a 52 week high of GBX 136 ($1.80). The firm has a market capitalization of £112.33 million, a price-to-earnings ratio of -6,650.00 and a beta of 0.58.

About Diaceutics

Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.